Mendus AB (publ) (STO:IMMU)

Sweden flag Sweden · Delayed Price · Currency is SEK
4.910
-0.140 (-2.77%)
Feb 10, 2026, 5:29 PM CET
Market Cap309.23M -21.4%
Revenue (ttm)n/a
Net Income-103.70M
EPS-2.03
Shares Out61.23M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume60,807
Average Volume29,183
Open4.955
Previous Close5.050
Day's Range4.910 - 5.280
52-Week Range4.175 - 10.980
Beta0.76
RSI43.00
Earnings DateFeb 11, 2026

About Mendus AB

Mendus AB (publ), a biopharmaceutical company, develops immunotherapies for the treatment of tumor recurrence and established tumors. Its lead product is vididencel (DCP-001), which is in Phase II ADVANCE-II clinical trial for the treatment of acute myeloid leukemia (AML); Phase II CADENCE clinical trial to treat AML; and Phase I ALISON clinical trial for the treatment of ovarian cancers. The company also develops ilixadencel, which is in phase 1/2 clinical trial for the treatment of soft tissue sarcomas; and an NK cell program, which is in a p... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2002
Employees 29
Stock Exchange Nasdaq Stockholm
Ticker Symbol IMMU
Full Company Profile

Financial Performance

Financial Statements